Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3358107 | 0.84 | MAOA (0.36) | MAOAMAOB | |
| SCHEMBL3357339 | 0.82 | TSHR (0.37) | MAOB | |
| SCHEMBL15062681 | 0.76 | MAOA (0.45) | MAOAMAOB | |
| SCHEMBL195110 | 0.74 | MAOA (0.65) | MAOAMAOB | |
| SCHEMBL3998995 | 0.73 | CYP1A2 (0.35) | MAOAMAOB | |
| Water SCHEMBL28306910 | 0.72 | MAOA (0.62) | MAOAMAOB | |
| SCHEMBL965211 | 0.72 | — | — | |
| SCHEMBL11194900 | 0.72 | GAA (0.33) | — | |
| SCHEMBL3352688 | 0.71 | TSHR (0.37) | MAOB | |
| SCHEMBL44758 | 0.70 | MAOA (0.65) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2023-02-21 | — | — | US | claimed |
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | claimed |
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | claimed |
| EP-4344702-A2 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| EP-4076662-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-01-31 | — | — | EP | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2023-02-21 | — | — | US | disclosed |
| US-11466003-B2 | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2022-10-11 | — | — | US | disclosed |
| US-20210300916-A1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-09-30 | — | — | US | disclosed |
| CN-110066277-B | Aromatic heterocyclic substituted olefin compound, preparation method, pharmaceutical composition and application thereof | 上海璎黎药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021124222-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-10-10 | — | — | US | disclosed |
| US-6420127-B1 | PREVENTION OF MICROORGANISMAL INFECTIONS; OBTAIN MEMBRANES, INCUBATE WITH MODULATORS, MONITOR MICROORGANISMAL INFECTIONS | WASHINGTON UNIVERSITY | 2002-07-16 | — | — | US | disclosed |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-04-18 | — | — | US | disclosed |
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-03-21 | — | — | US | disclosed |
| US-6153396-A | DRUG SCREENING BY ADDING COMPOUND TO MIXTURE OF CHAPERONE AND PILUS SUBUNIT AND DETERMINING THE CHANGE IN BINDING; BACTERICIDES FOR URINARY TRACT INFECTIONS | SIGA PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6001823-A | NOVEL PYRANOSIDES WHICH ARE BELIEVED TO BE CAPABLE OF INTERACTING WITH PERIPLASMIC MOLECULAR CHAPERONES | WASHINGTON UNIVERSITY | 1999-12-14 | — | — | US | disclosed |
| EP-0730601-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014028-A9 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | — | 1995-08-10 | — | — | WO | disclosed |
| WO-1995014028-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | MAOA 4275/4885MAOB 4621/4885 |
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | MAOA 3489/4885MAOB 2625/4885 |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | MAOA 3489/4885MAOB 2625/4885 |
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | ALK, ALKBH5, ALKBH3 | MAOA 333/4885MAOB 271/4885 |
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, NOTUM, WEE1 | MAOA 1811/4885MAOB 2060/4885 |
| US-11466003-B2 | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof | NOTUM, ALKBH5, PAH | MAOA 980/4885MAOB 1063/4885 |
| US-20210300916-A1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | NOTUM, ALKBH5, PAH | MAOA 980/4885MAOB 1063/4885 |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | MAOA 3489/4885MAOB 2625/4885 |
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | ALK, NOTUM, WEE1 | MAOA 1811/4885MAOB 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.